Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication (Q35594563)

9 August 2017

1 reference

title

Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication (English)

1 reference

9 August 2017

Cascorbi I

1

1 reference

9 August 2017

1 November 2003

1 reference

European Journal of Clinical Investigation

9 August 2017

1 reference

9 August 2017

33 Suppl 2

1 reference

9 August 2017

17-22

1 reference

Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs

9 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.3.X

Polymorphic hydroxylation of Debrisoquine in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.3.X

Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.3.X

Identification of the primary gene defect at the cytochrome P450 CYP2D locus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.3.X

CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.3.X

Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.3.X

Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.3.X

Metabolism of N,N-dialkylated amphetamines, including deprenyl, by CYP2D6 expressed in a human cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.3.X

Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.3.X

Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.3.X

Cytochromes P450 mediating the N-demethylation of amitriptyline

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.3.X

The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.3.X

CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.3.X

The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.3.X

The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.3.X

Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.3.X

Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.3.X

Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.3.X

Treatment of codeine dependence with inhibitors of cytochrome P450 2D6

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.3.X

Inhibition of cytochrome P450 2D6 modifies codeine abuse liability

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.3.X

Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.3.X

CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.3.X

Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.3.X

10.1046/J.1365-2362.33.S2.3.X

21 January 2018

Identifiers

DOI

1 reference

release_zh4qdrynz5aovjp6vqdhvekj4a

9 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zh4qdrynz5aovjp6vqdhvekj4a

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

14641552

1 reference

PubMed ID

14641552